Patents by Inventor Carl Alan Busacca

Carl Alan Busacca has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • STABILIZED PHARMACEUTICAL FORMULATIONS OF A POTENT HCV INHIBITOR
    Publication number: 20150190458
    Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.
    Type: Application
    Filed: March 20, 2015
    Publication date: July 9, 2015
    Inventors: Mathias BRAUN, Carl Alan BUSACCA, Feng-Jing CHEN, Edwin Louis GUMP, Jenness B. MAJESKA, Scott PENNINO, Fenghe QIU, Maria Fernanda VILLAGRA
  • STABILIZED PHARMACEUTICAL FORMULATIONS OF A POTENT HCV INHIBITOR
    Publication number: 20140037719
    Abstract: Described are various methods for stabilizing pharmaceutical formulations of a specific Hepatitis C Viral (HCV) inhibitor against the formation of a particular genotoxic degradation product. Such methods include temperature control, moisture control, excipient control, capsule shell control, basification and a reconstitution approach.
    Type: Application
    Filed: January 10, 2013
    Publication date: February 6, 2014
    Applicant: Boehringer Ingelheim International Gmbh
    Inventors: Mathias BRAUN, Carl Alan BUSACCA, Feng-Jing CHEN, Edwin Louis GUMP, Jenness B. MAJESKA, Scott PENNINO, Fenghe QIU, Maria Fernanda VILLAGRA
  • PROCESS FOR PREPARATION OF SUBSTITUTED P-AMINOPHENOL
    Publication number: 20130310597
    Abstract: The present invention is related to a process of preparing substituted p-aminophenol compound of formula (I) or a salt thereof,
    Type: Application
    Filed: July 23, 2013
    Publication date: November 21, 2013
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carl Alan BUSACCA, Magnus C. ERIKSSON, Jinghua XU, Xingzhong Zeng
  • Crystalline forms of a potent HCV inhibitor
    Patent number: 8362035
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: July 3, 2012
    Date of Patent: January 29, 2013
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR
    Publication number: 20120270775
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Application
    Filed: July 3, 2012
    Publication date: October 25, 2012
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
  • Crystalline forms of a potent HCV inhibitor
    Patent number: 8232293
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Grant
    Filed: September 15, 2009
    Date of Patent: July 31, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Thilo Berkenbusch, Carl Alan Busacca, Burkhard Jaeger, Richard J. Varsolona
  • Process for preparing macrocyclic compounds
    Patent number: 8222369
    Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN: The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: September 2, 2009
    Date of Patent: July 17, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Fabrice Gallou, Nizar Haddad, Azad Hossain, Suresh R. Kapadia, Jianxiu Liu, Chris H. Senanayake, Xudong Wei, Nathan K. Yee
  • Electronically tuned ligands for asymmetric hydrogenation
    Patent number: 8212049
    Abstract: Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands.
    Type: Grant
    Filed: June 28, 2011
    Date of Patent: July 3, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Jon Charles Lorenz
  • Process for preparing acyclic HCV protease inhibitors
    Patent number: 8101765
    Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: January 24, 2012
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Rogelio Perez Frutos, Nizar Haddad, Suresh R. Kapadia, Jon Charles Lorenz, Anjan Saha, Chris Hugh Senanayake, Xudong Wei
  • Electronically Tuned Ligands For Asymmetric Hydrogenation
    Publication number: 20110257393
    Abstract: Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands.
    Type: Application
    Filed: June 28, 2011
    Publication date: October 20, 2011
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carl Alan BUSACCA, Jon Charles LORENZ
  • Process for preparing acyclic HCV protease inhibitors
    Patent number: 8017771
    Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
    Type: Grant
    Filed: January 16, 2009
    Date of Patent: September 13, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Rogelio Perez Frutos, Nizar Haddad, Suresh R. Kapadia, Jon Charles Lorenz, Anjan Saha, Chris Hugh Senanayake, Xudong Wei
  • Electronically tuned ligands for asymmetric hydrogenation
    Patent number: 7994335
    Abstract: Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands.
    Type: Grant
    Filed: November 20, 2007
    Date of Patent: August 9, 2011
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Jon Charles Lorenz
  • CRYSTALLINE FORMS OF A POTENT HCV INHIBITOR
    Publication number: 20100093792
    Abstract: This invention relates to novel crystalline forms of the following Compound (1), and the sodium salt thereof, and methods for the preparation thereof, pharmaceutical compositions thereof, and their use in the treatment of Hepatitis C Viral (HCV) infection:
    Type: Application
    Filed: September 15, 2009
    Publication date: April 15, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Thilo BERKENBUSCH, Carl Alan BUSACCA, Burkhard JAEGER, Richard J. VARSOLONA
  • Electronically Tuned Ligands For Asymmetric Hydrogenation
    Publication number: 20100041898
    Abstract: Disclosed is a new class of chiral bidentate ligands capable of performing asymmetric hydrogenation. Also disclosed are processes of performing asymmetric hydrogenation the chiral bidentate ligands.
    Type: Application
    Filed: November 20, 2007
    Publication date: February 18, 2010
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Jon Charles Lorenz
  • PROCESS FOR PREPARING MACROCYCLIC COMPOUNDS
    Publication number: 20090326194
    Abstract: Disclosed is a process for preparing a macrocyclic compound of the formula (I) wherein a hydroxyl-substituted macrocyclic compound of formula (3) is reacted with a sulfonyl-substituted compound of formula QUIN: The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.
    Type: Application
    Filed: September 2, 2009
    Publication date: December 31, 2009
    Applicant: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan BUSACCA, Fabrice GALLOU, Nizar HADDAD, Azad HOSSAIN, Suresh R. KAPADIA, Jianxiu LIU, Chris SENANAYAKE, Xudong WEI, Nathan K. YEE
  • Process for preparing macrocyclic compounds
    Patent number: 7608614
    Abstract: Intermediates of the formula QUIN: and methods for their preparation are described. The intermediate compounds are useful for preparing active agents for the treatment of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: March 6, 2006
    Date of Patent: October 27, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Fabrice Gallou, Nizar Haddad, Azad Hossain, Suresh R. Kapadia, Jianxiu Liu, Chris Senanayake, Xudong Wei, Nathan K. Yee
  • Process for preparing macrocyclic compounds
    Patent number: 7544798
    Abstract: Disclosed is a multi-step process for preparing a macrocyclic compound of the formula (I): wherein Q is a radical of the following formula: and the other variables are as defined herein. The compounds of formula (I) are potent active agents for the treatment of hepatitis C virus (HCV) infection.
    Type: Grant
    Filed: February 1, 2007
    Date of Patent: June 9, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Vittorio Farina, Fabrice Gallou, Nizar Haddad, Xiao-jun Wang, Xudong Wei, Jinghua Xu, Yibo Xu, Nathan K. Yee, Li Zhang
  • PROCESS FOR PREPARING ACYCLIC HCV PROTEASE INHIBITORS
    Publication number: 20090124809
    Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
    Type: Application
    Filed: January 16, 2009
    Publication date: May 14, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carl Alan BUSACCA, Rogelio Perez FRUTOS, Nizar HADDAD, Suresh R. KAPADIA, Jon Charles LORENZ, Anjan SAHA, Chris Hugh SENANAYAKE, Xudong WEI
  • PROCESS FOR PREPARING ACYCLIC HCV PROTEASE INHIBITORS
    Publication number: 20090124808
    Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
    Type: Application
    Filed: January 16, 2009
    Publication date: May 14, 2009
    Applicant: BOEHRINGER INGELHEIM INTERNATIONAL GMBH
    Inventors: Carl Alan BUSACCA, Rogelio Perez FRUTOS, Nizar HADDAD, Suresh R. KAPADIA, Jon Charles LORENZ, Anjan SAHA, Chris Hugh SENANAYAKE, Xudong WEI
  • Process for preparing acyclic HCV protease inhibitors
    Patent number: 7514557
    Abstract: Disclosed are highly convergent processes for preparing compounds of formula (I), which compounds are potent active agents for the treatment of hepatitis C virus (HCV) infection: The disclosed processes use SNAr-type coupling reactions between peptidic compounds having a hydroxyproline moiety of the following formula: and halogenated or sulfonated bromoquinoline compounds.
    Type: Grant
    Filed: May 23, 2005
    Date of Patent: April 7, 2009
    Assignee: Boehringer Ingelheim International GmbH
    Inventors: Carl Alan Busacca, Rogelio Perez Frutos, Nizar Haddad, Suresh R. Kapadia, Jon Charles Lorenz, Anjan Saha, Chris Hugh Senanayake, Xudong Wei